Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.
Front Immunol. 2018 Mar 2;9:412. doi: 10.3389/fimmu.2018.00412. eCollection 2018.
The inflammatory chemokine (C-C motif) ligand 4 (CCL4) plays an important role in the pathogenesis and progression of cancer. In particular, higher serum CCL4 levels in patients with oral squamous cell carcinoma (OSCC) are associated with a more advanced stage of disease. OSCC accounts for approximately 95% of oral cancer in Taiwan and has a poor prognosis, due to aggressive local invasion and metastasis, leading to recurrence. OSCC spreads preferentially through lymphatic vessels and has the propensity to metastasize to the cervical lymph nodes even in the early stage of disease. Vascular endothelial growth factor C (VEGF-C) is an essential regulator of lymphangiogenesis. In particular, VEGF-C is specific to lymphatic vessel development, and VEGF-C expression levels have been found to directly correlate with lymph node metastasis in OSCC. However, it is unclear as to whether CCL4 correlates with VEGF-C expression and lymphangiogenesis in OSCC. We found that CCL4 increased VEGF-C expression and promoted lymphangiogenesis in oral cancer cells and . miR-195-3p mimic reversed CCL4-enhanced VEGF-C expression. CCL4 stimulation of oral cancer cells augmented JAK2 and STAT3 phosphorylation. Thus, CCL4 may be a new molecular therapeutic target for inhibition of lymphangiogenesis and metastasis in OSCC.
炎症趋化因子(C-C 基序)配体 4(CCL4)在癌症的发病机制和进展中起着重要作用。特别是,口腔鳞状细胞癌(OSCC)患者血清中 CCL4 水平较高与疾病的更晚期有关。OSCC 约占台湾口腔癌的 95%,由于侵袭性局部浸润和转移,导致复发,预后不良。OSCC 优先通过淋巴管扩散,即使在疾病的早期阶段也有向颈部淋巴结转移的倾向。血管内皮生长因子 C(VEGF-C)是淋巴管生成的重要调节剂。特别是,VEGF-C 特异性地促进淋巴管发育,并且发现 VEGF-C 表达水平与 OSCC 的淋巴结转移直接相关。然而,尚不清楚 CCL4 是否与 OSCC 中的 VEGF-C 表达和淋巴管生成相关。我们发现 CCL4 增加了口腔癌细胞中的 VEGF-C 表达并促进了淋巴管生成,miR-195-3p 模拟物逆转了 CCL4 增强的 VEGF-C 表达。CCL4 刺激口腔癌细胞增强了 JAK2 和 STAT3 的磷酸化。因此,CCL4 可能是抑制 OSCC 中的淋巴管生成和转移的新的分子治疗靶标。